William Duke Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 19,663 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $1.54, for a total value of $30,281.02. Following the transaction, the chief financial officer owned 128,681 shares in the company, valued at $198,168.74. This represents a 13.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Invivyd Trading Down 2.4%

Shares of NASDAQ IVVD opened at $1.61 on Friday. The stock has a market cap of $375.32 million, a P/E ratio of -3.43 and a beta of 0.60. Invivyd, Inc. has a twelve month low of $0.46 and a twelve month high of $3.07. The stock has a 50 day moving average of $2.17 and a two-hundred day moving average of $1.75.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IVVD shares. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. HC Wainwright raised their price target on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in IVVD. Invesco Ltd. increased its stake in shares of Invivyd by 67.6% during the fourth quarter. Invesco Ltd. now owns 293,580 shares of the company’s stock worth $725,000 after acquiring an additional 118,411 shares during the period. Ikarian Capital LLC lifted its position in Invivyd by 27.8% in the fourth quarter. Ikarian Capital LLC now owns 2,656,570 shares of the company’s stock valued at $6,562,000 after purchasing an additional 577,864 shares during the period. Virtus Investment Advisers LLC purchased a new stake in Invivyd in the 4th quarter valued at approximately $283,000. Quadrature Capital Ltd increased its position in Invivyd by 98.3% during the 4th quarter. Quadrature Capital Ltd now owns 91,241 shares of the company’s stock worth $225,000 after purchasing an additional 45,229 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in Invivyd during the 4th quarter worth approximately $53,809,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.